Movement Alert｜WUXI BIO Intraday Rise 3.09% in Regular Trading, FDA inspection tailwind continues to support sentiment

Market Focus10-28

On October 28, WUXI BIO rose 3.09% in Regular Trading, trading at HK$46.06, with turnover of HK$184 million.

The move was supported by continued positive market reaction to the company’s earlier disclosure that its Wuxi Mashan site passed an unannounced US FDA GMP on-site inspection with no major or critical findings.

The site is described as the first biologics manufacturing facility in China approved by both the FDA and EMA for commercial production, covering the full production system for multiple biologic drugs already approved in the US. The development reinforced confidence in WUXI BIO’s quality-control and commercial manufacturing capabilities. Broader strength in Life Sciences Tools & Services names, including WUXI APPTEC and WUXI XDC, also provided support to the share price.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment